Why Celcuity Stock Popped Today
On Thursday, Celcuity (NASDAQ: CELC) issued its final business update and set of financial results for 2025. Investors were particularly encouraged by the clinical-stage biotech's far narrower-than-expected net loss for the year's final quarter, and expressed their appreciation by bidding the stock up by more than 4% on the day.
Celcuity, which is currently in a pure research and development phase, did not report any revenue for either the fourth quarter or the full-year 2025. During the quarter, its operating expenses increased to over $49 million from over $36 million in the same period of 2024.
Image source: Getty Images.
Source Fool.com
